Company Profile

Fimbrion Therapeutics Inc
Profile last edited on: 1/28/21      CAGE: 5AAV6      UEI: N9RQX3G4EH54

Business Identifier: Drugs for treatment of anitbiotic resistant infectious diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

20 South Sarah Street
Saint Louis, MO 63108
   (860) 938-2315
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

Drawing down on work licensed from Washington Univesity, Fimbrion is organized around the discovery, development and commercialization pf antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including antibiotic-resistant strains. Pre-dating the firm's SBIR involvement, Fimbrion Therapeutic's management had put into place working relationship with GSK to work on development of a small-molecule drug for treatment and prevention of urinary tract infections

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Corinne Katherine Cusumano

  Thomas Hannan

  Thomas M Hooton

  Scott J Hultgren

  James Janetka -- Co-Founder Scientific Advisor

  Laurel Mcgrane

Company News

There are no news available.